Vobramitamab duocarmazine
Based on 1 Customer Validation
Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity.
For research use only. We do not sell to patients.
- Purity: 99.31%
- CAS No.: 2490556-51-7
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Vobramitamab duocarmazine (MGC018; for 7 days) exhibits cytotoxicity toward B7-H3-positive human tumor cell lines, including MDA-MB-468, A375.S2, PA-1, Calu-6, NCI-H1703, Hs700T, LN-229, and SW48 cancer cells, with IC50 values range of 181-1447 pM. Vobramitamab duocarmazine exhibited bystander killing of target-negative tumor cells when cocultured with B7-H3-positive tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) leads to a rapid tumor regression, with a 98% reduction in tumor volume in a triple-negative breast cancer patient-derived xenograft (PDX) model[1].
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) shows antitumor activity in the PA-1 ovarian cancer xenografts. A reduction in tumor volume of 89%, 91%, and 43%, is observed following treatment with Vobramitamab duocarmazine at 10, 6, and 3 mg/kg, respectively[1].
Vobramitamab duocarmazine (MGC018; 1-3 mg/kg; i.v; single-dose) shows antitumor activity in A375.S2 melanoma xenografts[1].
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) shows antitumor activity in Calu-6 lung cancer xenografts. A reduction in tumor volume of 91%, 84%, and 72% is observed following treatment with Vobramitamab duocarmazine at 10 mg/kg, 6 mg/kg, and 3 mg/kg, respectively[1].
Vobramitamab duocarmazine (MGC018; 3 mg/kg; QW×3 or Q2W×2; i.v) shows antitumor activity toward patient-derived xenograft models of prostate, and head and neck cancer displaying heterogeneous expression of B7-H3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CD-1 nude (homozygous) mice (Crl:CD1-Foxn1nu) and female SCID/CES1c KO mice (5-7 weeks old) injected with MDA-MB-468 cells[1]
-
Dosage:3 mg/kg, 6 mg/kg
-
Administration:Tail vein injection; a single-dose
-
Result:Led to a dose-dependent decrease in tumor growth of MDA-MB-468 triple-negative breast cancer xenografts.
-
Animal Model:Female Athymic Nude-Foxn1nu mice (triple-negative breast cancer models)[1]
-
Dosage:3 mg/kg
-
Administration:Tail vein injection; once a week; for 2 weeks
-
Result:Led to a rapid tumor regression, with a 98% reduction in tumor volume.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2490556-51-7
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Vobramitamab duocarmazine]
-
Synonyms
AEX4089DC1; MGC018
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vobramitamab duocarmazine Related Classifications
HY-145636 Related Classifications
Powered by Bioz